[Evaluation of carbetocin (pabal) efficacy in the prevention of the postpartum hemorrhage in women after cesarean section--preliminary report].
OBJECTIVE
The aim of this study was to evaluate the efficacy of carbetocin in prevention of PPH in women after cesarean section.


METHODS
We enrolled 60 patients who had undergone cesarean section in tertiary referential center, Department of Perinatology, Medical University of Lodz, Poland, between January and June 2008. Each patient obtained a single 100 microg dose of carbetocin intravenously during cesarean section, immediately after the delivery of the baby and prior to the delivery of the placenta. We evaluated postoperative blood parameters in 2 and 12 hours after the operation, the proportion of patients requiring additional uterotonic agents and adverse events in the whole population and in the group of women with high risk of PPH.


RESULTS
58.1% of patients underwent emergency and 41.3% elective cesarean section delivery. The risk factor of PPH was identified in 38 women (63.3%). The results of this study indicate that carbetocin produces rapid and long-lasting uterine tone. A small drop in mean hemoglobin and hematocrit levels 2 and 12 hours after the operation was observed. 15% of patients required the use of additional uterotonic agents. In the group of women with high risk of PPH, carbetocin appeared to be effective in 79% of the patients. Only 11.4% of patients had minor adverse events.


CONCLUSIONS
Carbetocin appears to be an effective new drug in the prevention of postpartum hemorrhage, not only among women undergoing cesarean section but also in the group of women with PPH risk factors.
Kalinka
Jarosław
J
Pracownia Medycznych i Srodowiskowych Zagrozen Ciazy, Klinika Perinatologii, I Katedry Ginekologii i Połoznictwa, Uniwersytetu Medycznego w Lodzi. j.kalinka@csk.am.lodz.pl
Lipińska
Małgorzata
M
Sosnowski
Dariusz
D
Wiliński
Wojciech
W
Skoczylas
Michał
M
Serafin
Marcin
M
Prośniewska
Maria
M
Krajewski
Paweł
P
Laudański
Tadeusz
T
D000328:Adult; D002585:Cesarean Section / Q000009:adverse effects*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007430:Intraoperative Care; D010121:Oxytocin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011044:Poland; D019106:Postoperative Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006473:Postpartum Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D011247:Pregnancy; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D010121:Oxytocin; C020731:carbetocin